The ABRE study difference: complex and diverse set of patients

  • 47.5% categorized as PTS patients.
  • 35.8% of PTS patients presented with complete vein occlusion.
  • 44% of patients with stents extending below inguinal ligament.
  • 112.4 mm average lesion length.

Quality of life and venous functional scores: EQ5D, VEINES, Villalta, VCSS

EQ5D index score

VEINES-QoL§

Villalta

VCSS


Primary patency#

36-month patency

81.6% 
overall

NIVL 97.1% 
aDVT 76.5% 
PTS 70.4%

24-month patency

86.2% 
overall

NIVL 98.6% 
aDVT 83.3% 
PTS 76.8%

12-month patency

93.2% 
overall

NIVL 98.6% 
aDVT 100% 
PTS 86.4%

Primary safety end point

98.0% freedom from MAEs at 30 days.

Complications
Cumulative incidence
(based on Kaplan-Meier estimate)
36 months (within 1,080 days)
N = 200 subjects
TLR 16.3% (32)
MAE 10.2% (20)
    All-cause death occurring post-procedure 1.5% (3)
    Clinically significant pulmonary embolism 2.1% (4)
    Major bleeding complication (post-procedure) 0.5% (1)
    Stent thrombosis 6.1% (12)
    Stent migration 0.0% (0)
Major bleeding related to index procedure 0.0% (0)

Secondary end points

  • 83.7% freedom from TLR at 36 months.††
  • 0.0% stent fracture at 36 months.‡‡
  • 0.0% delayed stent migration at 36 months.§§

Abre™ clinical study design

Purpose and indication

Evaluate the safety and effectiveness of the Abre™ venous self-expanding stent system, intended for the treatment of symptomatic iliofemoral venous outflow obstruction

Sample size

200 subjects

Initial clinical presentation

Acute DVT, post-thrombotic syndrome (PTS), and nonthrombotic iliac vein lesion (NIVL)

Follow-up

1, 6, 12, 24, and 36 months

Study design
  • Prospective, multicenter, single-arm
  • Designed to meet literature-based performance goals: 
    • 12-month primary effectiveness endpoint◊◊
    • 30-day primary safety endpoint¶¶

Baseline demographics

Demographics Included subjects
Age (years) (mean ± SD) 51.5 ± 15.9 
Age (< 50 years)
41.5% (83/200)
Female 66.5% (133/200)
BMI (kg/m²) (mean ± SD) 29.5 ± 7.1

Baseline medical history

Medical history Included subjects

Previous history of venous thromboembolism

52.0% (104/200)

Hypertension

31.0% (62/200)

Venous claudication

30.0% (60/200)

Known family history of DVT

22.0% (44/200)

Pulmonary embolism

17.0% (34/200)

Smoking (active)

12.0% (24/200)

Thrombophilia

11.5% (23/200)

Cancer (ongoing or remission)

11.0% (22/200)

IVC filter present

5.0% (10/200)

Procedural data

Assessment Included subjects

Target limb — left

92% (184/200)

Reference vessel diameter (mm) (mean ± SD)

15.0 ± 2.7

% Area stenosis (mean ± SD)##

74.9 ± 16.8

% Diameter stenosis (mean ± SD)

62.8 ± 28.7

Subjects with occluded lesions

25.6% (50/195)

Lesion length (mm) (mean ± SD)  

112.4 ± 66.1

Total stented length (mm) (mean ± SD)

134.3 ± 58.0

Number of Abre™ stents implanted per subject

1.5 ± 0.6 

Stented vein location

    Common iliac vein

96.0% (192/200)

    External iliac vein

80.5% (161/200)

    Common femoral vein

44.0% (88/200)